Nandi J. Reddy - Concepedia

Author

Nandi J. Reddy

Also Known As

N J Reddy, N REDDY, N. J. Reddy, N. Jaipal Reddy, N. Nagi Reddy, N. Reddy, N.J. Reddy, N.Sahasra Reddy, Nagireddy Vishnu Vardhan Reddy, Nandi J. Reddy

Publications

628

Citations

H-Index

Concepts

All Affiliations

Dartmouth–Hitchcock Medical Center GlaxoSmithKline (United States)Dr. Reddy's Foundation Research Triangle Park Foundation University of Pennsylvania

About

Nandi J. Reddy is an author at Dartmouth–Hitchcock Medical Center specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	78
2	Engineering	1	1	10
3	Natural Sciences	1	1	57
4	Biochemistry	1	1	57
5	Biomolecular Engineering	1	1	10

Nandi J. Reddy

Publications

510

Citations

H-Index

Page 1

	Year	Citations
Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients Kevin M. Koch, Nandi J. Reddy, Roger B. Cohen, Journal of Clinical Oncology	2009	138
Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers Nancy Lewis, Lionel D. Lewis, Joseph P. Eder, Journal of Clinical Oncology	2009	92
An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors Brian C. Goh, Nandi J. Reddy, Uday B. Dandamudi, Clinical Pharmacology & Therapeutics	2010	82
Novel Euglycemic and Hypolipidemic Agents. 4. Pyridyl- and Quinolinyl-Containing Thiazolidinediones Braj B. Lohray, Vidya Bhushan, A. Sekar Reddy, Journal of Medicinal Chemistry	1999	59
Novel Antidiabetic and Hypolipidemic Agents. 5. Hydroxyl versus Benzyloxy Containing Chroman Derivatives K. Anji Reddy, Braj B. Lohray, V. Bhushan, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ChemistryPharmaceutical ScienceBiochemistryMedicine	1999	57
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation Kelsey S. Lau‐Min, Lisa A. Varughese, Maria N. Nelson, BMC Cancer	2022	33
A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors A. W. Tolcher, S. Antonia, Lionel D. Lewis, Journal of Clinical Oncology ApoptosisHour Continuous InfusionCell DeathPathologyPharmacotherapy	2006	21
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing Lisa A. Varughese, Madhuri Bhupathiraju, Glenda Hoffecker, Frontiers in Oncology	2022	18
Stereoselective Total Synthesis of (-)-Colletol by Prins Cyclisation J. S. Yadav, Nandi J. Reddy, Police Vishnuvardhan Reddy, Synthesis EngineeringYamaguchi MacrolactonisationOrganic ChemistryPyran RingPrins Cyclisation	2010	10

Page 1